^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastroesophageal Junction Adenocarcinoma

    Related cancers:
    1d
    AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2) (clinicaltrials.gov)
    P=N/A, N=6000, Not yet recruiting, Imperial College London
    New trial
    2d
    Pre-CATALIS: Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P=N/A, N=67, Not yet recruiting, Shanghai Zhongshan Hospital
    New trial • Mismatch repair • MSI-H • dMMR
    3d
    Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric Cancer With Neoadjuvant Treatment: An Adaptive Trial (MRD-ATLAS) (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Shanghai Zhongshan Hospital
    New P2 trial • Minimal residual disease • Circulating tumor DNA
    |
    5-fluorouracil • capecitabine • oxaliplatin
    3d
    A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA) (clinicaltrials.gov)
    P3, N=703, Completed, Hutchison Medipharma Limited | Active, not recruiting --> Completed
    Trial completion
    |
    paclitaxel • Fruzaqla (fruquintinib)
    3d
    NIRADO: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (clinicaltrials.gov)
    P2, N=51, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Dec 2027 --> Feb 2025 | Suspended --> Terminated; Abandon of the partner, GSK
    Trial completion date • Trial termination • Pan tumor • Platinum sensitive
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ARID1A (AT-rich interaction domain 1A) • PBRM1 (Polybromo 1) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • ARID2 (AT-Rich Interaction Domain 2) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    HER-2 positive • HER-2 amplification • DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    4d
    ARIANES: Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (clinicaltrials.gov)
    P2, N=130, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Suspended --> Terminated; Bankruptcy of partner: Clovis
    Trial termination • Pan tumor • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • IL2 (Interleukin 2) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Tecentriq (atezolizumab) • Rubraca (rucaparib)
    4d
    A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers (clinicaltrials.gov)
    P1, N=123, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2026 --> May 2026 | Trial primary completion date: Dec 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • Actemra IV (tocilizumab) • runimotamab (RG6194)
    4d
    Phase 1b/2 Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma. (PubMed, Clin Cancer Res)
    Zanidatamab, in combination with tislelizumab and CAPOX, demonstrated clinically meaningful antitumor activity with a manageable safety profile as first-line therapy for patients with HER2+ GC/GEJC. These results support further development of zanidatamab and tislelizumab with chemotherapy in this patient population in the ongoing phase 3 HERIZON-GEA-01 trial (NCT05152147).
    P1/2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Ziihera (zanidatamab-hrii)
    4d
    Soluble TIM-3 and galectin-9 predict survival in gastric and gastroesophageal junction cancer. (PubMed, iScience)
    Patients with GC/GEJ with increased sTIM-3 and sGal-9 levels had a significantly reduced overall survival with a hazard ratio of 1.77 (sTIM-3 high), 1.82 (sGal-9 high), and 2.27 (sTIM-3 high+sGal-9 high), respectively. Collectively, sTIM-3 and sGal-9 may serve as novel non-invasive biomarkers for diagnosis and outcome prediction in patients with GC/GEJ.
    Journal • IO biomarker
    |
    HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CA 19-9 (Cancer antigen 19-9) • LGALS9 (Galectin 9)
    4d
    Involvement of long non-coding RNA NORAD in short-term poor prognosis of neoadjuvant chemotherapy in adenocarcinoma of esophagogastric junction. (PubMed, Ann Med)
    High pretreatment NORAD expression is an independent risk factor for poor response to neoadjuvant chemotherapy. Downregulating NORAD restores oxaliplatin sensitivity in resistant cells.
    Journal
    |
    NORAD (Non-Coding RNA Activated By DNA Damage)
    |
    oxaliplatin
    6d
    Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=88, Recruiting, West China Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tyvyt (sintilimab) • oxaliplatin
    6d
    Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=84, Enrolling by invitation, West China Hospital | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    paclitaxel • Teysuno (gimeracil/oteracil/tegafur)